ElpasBio Completes Phase III Enrollment for AlloJoin Stem Cell Therapy in Knee Osteoarthritis
核心洞察
ElpasBio completed patient enrollment of over 500 participants in its Phase III pivotal trial of AlloJoin, an allogeneic stem cell therapy for knee osteoarthritis treatment.
The trial represents the world's first dual-primary-endpoint clinical study designed for disease modification of knee osteoarthritis, targeting a patient population expected to reach 160 million in China by 2025.
The company plans to read out Phase III data in 2027 and submit a New Drug Application to Chinese regulators, with commercialization support from partner Fosun Kairos (搜索).
ElpasBio Holdings (搜索) announced the completion of patient enrollment in its Phase III pivotal clinical trial of AlloJoin (lotazadromcel (搜索)), marking a significant milestone for one of the few stem cell product candidates in late-stage clinical development worldwide. The Shanghai-based biotechnology company enrolled over 500 patients in May 2026 for the trial evaluating its allogeneic human adipose-derived mesenchymal stem cell therapy for knee osteoarthritis treatment.
Breakthrough Trial Design for Disease Modification
The Phase III study represents the world's first dual-primary-endpoint clinical trial specifically designed for disease modification of knee osteoarthritis. AlloJoin is being investigated for its potential to provide safe and durable symptom relief by suppressing inflammation and promoting the repair of damaged cartilage, with the ambitious goal of becoming the world's first regenerative medicine product capable of modifying knee osteoarthritis progression.
"The Phase III clinical trial of AlloJoin is the world's first dual-primary-endpoint clinical trial designed for disease modification of KOA," stated Tony (Bizuo) Liu, Chairman of ElpasBio. "The completion of efficient enrollment of over 500 patients reaffirmed the huge unmet medical need."
Proprietary Technology Platform
AlloJoin is ElpasBio's core investigational, off-the-shelf stem cell product, developed entirely in-house based on its proprietary human adipose-derived mesenchymal stem cell (haMPC) technology platform. The therapy is protected by independent intellectual property rights and represents the first stem cell drug in China approved to enter Phase III clinical trial for knee osteoarthritis treatment.
Regulatory Timeline and Commercialization Strategy
ElpasBio plans to read out data from the Phase III pivotal study in 2027 and submit a New Drug Application to the Center for Drug Evaluation of the National Medical Products Administration of China later the same year. The company has established a strategic partnership with Fosun Kairos (搜索), entering into a commercialization collaboration agreement on January 14, 2026, for AlloJoin treatment of knee osteoarthritis in Mainland China, Hong Kong SAR, and Macau SAR.
Under the partnership agreement, ElpasBio will continue to be responsible for development, regulatory registration, and manufacturing of AlloJoin in these territories while retaining all commercialization rights outside these regions.
Addressing Significant Unmet Medical Need
Knee osteoarthritis is an age-related degenerative joint disease characterized by joint pain, stiffness, and functional impairment that significantly impacts patients' quality of life. With China's rapidly aging population, the number of osteoarthritis patients in China is expected to reach approximately 160 million by 2025. Current common drug-based management methods provide limited improvement, highlighting the critical importance of developing novel therapies to address significant unmet clinical needs.
Company Background and Expertise
ElpasBio Holdings (搜索) is a clinical-stage biotechnology company focused on regenerative medicine that was spun off from AbelZeta Pharma, Inc. (previously known as CBMG Holdings) in 2023. The company completed over $10 million in seed round financing in 2025 and brings more than 15 years of expertise in the stem cell field, having developed and explored multiple stem cell products across autologous and allogeneic approaches and various cell sources.
The company operates GMP-compliant manufacturing and R&D facilities in Wuxi and Shanghai, China, positioning it to support the development and potential commercialization of AlloJoin and other regenerative medicine products in its pipeline.